124 related articles for article (PubMed ID: 19560446)
1. Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population.
Ma JJ; Liu CG; Li JH; Cao XM; Sun SL; Yao X
Clin Chim Acta; 2009 Sep; 407(1-2):30-5. PubMed ID: 19560446
[TBL] [Abstract][Full Text] [Related]
2. N-Acetyltransferase 2 genotype correlates with sulfasalazine pharmacokinetics after multiple dosing in healthy Japanese subjects.
Kita T; Sakaeda T; Adachi S; Sakai T; Aoyama N; Hatanaka H; Kasuga M; Okumura K
Biol Pharm Bull; 2001 Oct; 24(10):1176-80. PubMed ID: 11642327
[TBL] [Abstract][Full Text] [Related]
3. N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis.
Kumagai S; Komada F; Kita T; Morinobu A; Ozaki S; Ishida H; Sano H; Matsubara T; Okumura K
Pharm Res; 2004 Feb; 21(2):324-9. PubMed ID: 15032315
[TBL] [Abstract][Full Text] [Related]
4. N-acetyltransferase 2 genotype-related sulfapyridine acetylation and its adverse events.
Tanigawara Y; Kita T; Aoyama N; Gobara M; Komada F; Sakai T; Kasuga M; Hatanaka H; Sakaeda T; Okumura K
Biol Pharm Bull; 2002 Aug; 25(8):1058-62. PubMed ID: 12186410
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans.
Yamasaki Y; Ieiri I; Kusuhara H; Sasaki T; Kimura M; Tabuchi H; Ando Y; Irie S; Ware J; Nakai Y; Higuchi S; Sugiyama Y
Clin Pharmacol Ther; 2008 Jul; 84(1):95-103. PubMed ID: 18167504
[TBL] [Abstract][Full Text] [Related]
6. Phenotyping with sulfasalazine - time dependence and relation to NAT2 pharmacogenetics.
Kuhn UD; Anschütz M; Schmücker K; Schug BS; Hippius M; Blume HH
Int J Clin Pharmacol Ther; 2010 Jan; 48(1):1-10. PubMed ID: 20040334
[TBL] [Abstract][Full Text] [Related]
7. Kinetic phenotypic diagnosis of N-acetylation polymorphism in patients based on ratio of urinary metabolites of salicylazosulfapyridine.
Yokogawa K; Nakaharu T; Ishizaki J; Ozaki E; Takeda Y; Mabuchi H; Matsushita R; Kimura K; Nakashima E; Ichimura F; Miyamoto K
Int J Pharm; 2001 Oct; 229(1-2):183-91. PubMed ID: 11604271
[TBL] [Abstract][Full Text] [Related]
8. N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease.
Chen M; Xia B; Chen B; Guo Q; Li J; Ye M; Hu Z
Can J Gastroenterol; 2007 Mar; 21(3):155-8. PubMed ID: 17377643
[TBL] [Abstract][Full Text] [Related]
9. The influence of multiple oral doses of zileuton on the steady-state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N-acetylsulfapyridine.
Awni WM; Braeckman RA; Locke CS; Dubé LM; Granneman GR
Clin Pharmacokinet; 1995; 29 Suppl 2():98-104. PubMed ID: 8620678
[TBL] [Abstract][Full Text] [Related]
10. Toxicokinetics of sulfasalazine (salicylazosulfapyridine) and its metabolites in B6C3F1 mice.
Zheng W; Winter SM; Mayersohn M; Bishop JB; Sipes IG
Drug Metab Dispos; 1993; 21(6):1091-7. PubMed ID: 7905389
[TBL] [Abstract][Full Text] [Related]
11. Arylamine N-acetyltransferase polymorphisms in Han Chinese patients with ankylosing spondylitis and their correlation to the adverse drug reactions to sulfasalazine.
Hou ZD; Xiao ZY; Gong Y; Zhang YP; Zeng QY
BMC Pharmacol Toxicol; 2014 Nov; 15():64. PubMed ID: 25413361
[TBL] [Abstract][Full Text] [Related]
12. Gene dose effect of NAT2 variants on the pharmacokinetics of isoniazid and acetylisoniazid in healthy Chinese subjects.
Bing C; Xiaomeia C; Jinhenga L
Drug Metabol Drug Interact; 2011; 26(3):113-8. PubMed ID: 21980963
[TBL] [Abstract][Full Text] [Related]
13. Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study.
Gu GZ; Xia HM; Pang ZQ; Liu ZY; Jiang XG; Chen J
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Feb; 879(5-6):449-56. PubMed ID: 21251889
[TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacokinetics of sulphasalazine and sulphapyridine after rectal and oral administration to patients with ulcerative colitis.
Allgayer H; Kruis W; Eisenburg J; Paumgartner G
Eur J Clin Pharmacol; 1984; 26(2):275-7. PubMed ID: 6144549
[TBL] [Abstract][Full Text] [Related]
15. The influence of various genotypes on the metabolic activity of NAT2 in a Chinese population.
Chen B; Zhang WX; Cai WM
Eur J Clin Pharmacol; 2006 May; 62(5):355-9. PubMed ID: 16570187
[TBL] [Abstract][Full Text] [Related]
16. [Ulcerative colitis in children. Levels of salicylazosulfapyridine and sulfapyridine during treatment].
Guastavino E; Litwin NH; Heffes Nahmod L; Licastro R
Acta Gastroenterol Latinoam; 1988; 18(2):107-13. PubMed ID: 2908013
[TBL] [Abstract][Full Text] [Related]
17. Effects of dialysis on the pharmacokinetics of salazosulfapyridine.
Inami Y; Yamaji K; Sato M; Gohda T; Io H; Nawata M; Hamada C; Takasaki Y; Tomino Y
Rheumatol Int; 2013 Feb; 33(2):535-9. PubMed ID: 22080212
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacokinetics of salazosulfapyridine in a hemodialysis patient].
Akiyama Y; Fujimaki T; Sakurai Y
Ryumachi; 2003 Jun; 43(3):569-76. PubMed ID: 12910967
[TBL] [Abstract][Full Text] [Related]
19. Polymorphism of N-acetyltransferase 2 (NAT2) gene polymorphism in shanghai population: occupational and non-occupational bladder cancer patient groups.
Ma QW; Lin GF; Chen JG; Xiang CQ; Guo WC; Golka K; Shen JH
Biomed Environ Sci; 2004 Sep; 17(3):291-8. PubMed ID: 15602826
[TBL] [Abstract][Full Text] [Related]
20. Sulfasalazine metabolite pharmacokinetics in pediatric patients with inflammatory bowel disease: effects of disease activity, acetylator phenotype, and age.
Clarke DF; George D; Milsap RL; Pogonowska-Wala E; Owerbach J; Lebenthal E; Jusko WJ
Pediatr Pharmacol (New York); 1982; 2(4):323-33. PubMed ID: 6152489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
